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LETTER TO THE EDITOR
Resistance trends and epidemiology of Aeromonas
and Plesiomonas infections (RETEPAPI): a 10-year
retrospective survey
To the Editor,
A high incidence of resistance among Gram-negative
isolates from patients in a Lithuanian cancer centre was
recently reported in this journal [1]. Multidrug resistance
was observed in 55, 82, 95 and 97% of Escherichia coli,
Enterobacter spp., Klebsiella pneumoniae and
Acinetobacter baumannii isolates, respectively. Herein,
we report the resistance data on Aeromonas and
Plesiomonas species at a tertiary-care hospital in
Hungary during a 10-year period, a period which to find
trends, is divided in a 2008–2012 and a 2013–2017
period. The genera Aeromonas and Plesiomonas are oxi-
dase-positive, glucose-fermenting Gram-negative rods
(they can be phenotypically distinguished, based on the
ability of Aeromonas to ferment inulin), that are mem-
bers of the Enterobacterales order [2,3]. These bacteria
are ubiquitous in marine environments (freshwater,
drinking water, wastewater sites, in addition to fish,
amphibians and reptilians) and can survive osmotic
stress (high salt concentrations), but their isolation from
processed food products has also been described [4].
Although Aeromonas and Plesiomonas may be isolated
from asymptomatic individuals, these pathogens have
been implicated in a wide range of infectious processes,
due to the plethora of virulence factors they possess,
such as toxins (incl. enterotoxins), polar flagella, pili,
adhesins, lipases, proteases, haemolysin and a Type-VI
secretion system [2,4–6]. Among the Aeromonas genus,
only the motile, mesophilic species are capable of caus-
ing diseases in mammals and humans [2,4].
This study was carried out using microbiological data
collected between 01 January 2008 and 31 December
2017 at the SZTE Albert Szent-Gy€orgyi Clinical Centre, an
academic primary and tertiary-care teaching hospital in
Szeged, Hungary, which has a bed capacity of
1820-beds and annually serves more than 400,000
patients in the region. An electronic search of the
laboratory information system (LIS) records was con-
ducted. Isolates were considered separate if they
occurred >14 days apart or isolates with different anti-
biotic susceptibilities were detected. Data on affected
patients were also collected, which was limited to demo-
graphic characteristics (age, sex and inpatient/outpatient
status), indication for sample submission and the admin-
istered empiric antibiotic therapy.
The processing of samples arriving to our Institute
was carried out according to guidelines in routine clin-
ical bacteriology. Relevant culture media plates were
incubated at 37 C for 24–48 h, aerobically. If Aeromonas
or Plesiomonas species presented in significant colony
count, the plates were passed on for further processing.
Between 2008 and 2012, presumptive phenotypic/bio-
chemical methods and VITEK 2 Gr- ID (bioMerieux,
Marcy-l’Etoile, France) were used for bacterial identifica-
tion, while after 2013, this was complemented by
matrix-assisted laser desorption/ionization time-of-flight
mass spectrometry (MALDI-TOF MS; Bruker Daltonik
GmbH., Bremen, Germany) [7,8]. Sample preparation and
settings for MALDI-TOF MS measurements is described
elsewhere.
Routine antimicrobial susceptibility testing in our
Institute was performed for ciprofloxacin, ceftriaxone,
cefepime, doxycycline, gentamicin, meropenem, sulpha-
methoxazole/trimethoprim and tigecycline, using disk
diffusion. Interpretation of the results was based on CLSI
criteria (CLSI guideline M45; https://clsi.org/standards/
products/microbiology/documents/m45/). Staphylococcus
aureus ATCC 29213, Enterococcus faecalis ATCC 29212,
E. coli ATCC 25922 and Pseudomonas aeruginosa ATCC
27853 were used as quality control strains.
Descriptive statistical analysis (including means or
medians with ranges and percentages to characterize
data) was performed using Microsoft Excel 2013
(Microsoft Corp., Redmond, WA). Statistical analyses
were performed with SPSS software version 24 (SPSS,
Chicago, IL, USA) (IBM SPSS Statistics for Windows ver-
sion 24.0, IBM Corp., Armonk, NY), using the v2-test,
Student’s t-test and Mann–Whitney U test. The normality
of variables was tested using Shapiro–Wilk tests. p < .05
were considered statistically significant.
A total of 193 individual isolates were identified (n ¼
193; 19.3 ± 12.3/year, highest in 2015 and lowest in
2010) from various sample types during the 10-year
study period. The number of isolates between 2008 and
2012 was n ¼ 46 (9.2 ± 4.2/year, range: 5–16) while for
2013–2017, this number was n ¼ 147 (29.4 ± 8.2/year,
range: 18–38); the difference in the isolation frequency
was statistically significant (p ¼ .0012). 51.8% of isolates
originated from inpatient departments (p > .05). 75.6%
of isolates were identified in the period between May
and September of the relevant year. Most of the isolates
were Aeromonas spp. (97.9%; namely: Aeromonas hydro-
phila 45.6%, Aeromonas caviae 36.7%, Aeromonas veronii
13.2%, Aeromonas salmonicida 3.3%, Aeromonas bestia-
rum 1.1% and Aeromonas ichtiosima 1.1%), while
Plesiomonas shigelloides isolates were fewer (2.1%, one
isolate in 2008, 2012, 2014 and 2016, respectively).
Before 2013, A. hydrophila and A. caviae were mainly
isolated.
The patients affected presented no relevant domin-
ance towards either sex (female-to-male ratio: 0.97;
49.2% female; p<.05). The median age of the affected
patients was 61 years overall (range: 2–99 years),
however, in the second half of the study period, a
pronounced shift towards older patients was detected
(median2008–2012 ¼ 46 years, range: 2–79 vs.
median2013–2017 ¼ 71 years, range: 3–99; p < .0001). The
age distribution of patients was the following: 11.2%
0–18 years, 7.1% 19–29 years, 8.2% 30–45 years, 10.2%
46–59 years and 63.3% of patients were older than
60 years. Wounds samples (lacerations, punctures and
avulsions) were the most common sample type (27.4%),
followed by abscesses and surgical samples (18.2%),
high vaginal swabs and cervical samples (10.2%), mid-
stream urine and urethral swabs, lower respiratory tract
samples (7.9% each), blood cultures and feces (6.8%
each), inner ear puncuture (5.7%), bile (4.5%) and sinus
aspirates and semen (2.3% each). Indications for sample
submission, associated with the isolation of these patho-
gens included skin ulcers (20.4%), cholecystitis and gall
stones (15.1%), septicaemia, solid tumours or hemato-
logical malignancy (10.9% each), wound infections
(8.3%), vaginitis, diarrhoea (7.3% each), dermatitis, urin-
ary tract infections, cystic fibrosis (5.2% each) and inner
ear infections (4.2%). In most cases, the reported empiric
therapy was ampicillin (70.9%), followed by piperacillin/
tazobactam (19.8%), amoxicillin/clavulanic acid (4.1%),
ceftriaxone, ceftazidime (1.6% each) and gentamicin and
imipenem (1.0% each).
The resistance trends of relevant species during the
study period is presented in Table 1. The highest resist-
ance levels overall were observed for ceftriaxone
(20%), sulphamethoxazole/trimethoprim (18%), cipro-
floxacin (14%) and cefepime (13.0%). Meropenem
resistance was also above 10%, while resistance rates
agaist doxycycline, tigecycline and gentamicin were
around or lower, than 5%. There was a significant
increase in the number of resistant isolates correspond-
ing to ceftriaxone, sulphamethoxazole/trimethoprim and
meropenem, while a drop was noted in case of doxycyc-
line. No statistical tendency was observed for ciprofloxa-
cin, cefepime and tigecycline. Relevant differences in the
susceptibility trends of A. hydrophila and A. caviae (the
two most numberus species) were not detected (p>.05).
Aeromonas and Plesiomonas species are emerging
pathogens in the twenty-first century, especially since
laboratory technology (MALDI-TOF MS, polymerase chain
reaction and whole-genome sequencing) is available to
identify them swifly and reliably [2,4]. These bacteria
mainly act as pathogens in pathologies affecting the
skin and gastrointestinal tract, which was verified by our
local results; however, uncommon presentations, such as
genitourinary infections, cholecystitis, invasive infections
and bacteremia were also noted locally. The temporal
nature of their isolation (both regarding the age of
affected patients and their isolation frequency in warmer
months) was also verified, while the male dominance in
our settings was not present. Skin infections are more


















Overall 13.9% 19.8% 13.0% 5.2% 3.6% 10.9% 17.7% 1.0%
n ¼ 15 n ¼ 38 n ¼ 25 n ¼ 10 n ¼ 7 n ¼ 21 n ¼ 34 n ¼ 2
2008–2012 18.8% 29.6% 27.2% 22.7% 9.1% 15.9% 25.0% 4.6%
n ¼ 8 n ¼ 13 n ¼ 13 n ¼ 10 n ¼ 4 n ¼ 7 n ¼ 11 n ¼ 2
2013–2017 4.7% 16.9% 8.8% 0% 2.0% 9.5% 15.5% 0%
n ¼ 7 n ¼ 25 n ¼ 12 n ¼ 0 n ¼ 3 n ¼ 14 n ¼ 23 n ¼ 0
Statistics p>.05 p¼.036 p>.05 p¼.047 p>.05 p¼.038 p¼.04 p>.05
CIP: ciprofloxacin; CRO: ceftriaxone; FEP: cefepime; DOX: doxycycline; GEN:
gentamicin; MER: meropenem; SUM: sulphamethoxazole/trimethoprim; TIG:
tigecycline.
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common in regions affected by natural disasters (floods
and tsunamis) and in individuals working near aquatic
environments or with fish/animals, especially if an
underlying disease/trauma is present [2,4,5]. Based on
retrospective analyses, Aeromonas species were causa-
tive agents of traveller’s diarrhoea in 2–5% of cases [4].
These cases are usually self-limiting, and the addition of
antibiotic therapy to complement rehydration is only
necessary if the symptoms do not cease after a reason-
able period of time [2,4,5]. However, enterocolitis with
haemolytic uremic syndrome (HUS) has also been
described [9]. While uncommon in Western countries,
bacteraemia and severe Aeromonas wound infections
were associated with the medicinal use of leeches [10].
Septicaemia and severe manifestations have been asso-
ciated with advanced age, malignant diseases and poli-
traumatization in the literature [2,4,5,9,10].
As there are no strict guidelines for the therapy of
Aeromonas/Plesiomonas infections, therapeutic decisions
are mainly based on monitoring clinical response.
Education of clinicians is a must, as we observed that
more than two-thirds of patients were treated with
ampicillin empirically, which is not a viable therapeutic
option in these infections [2,4,5]. Based on Infectious
Diseases Society of America (IDSA) guidelines, empiric
therapy is not recommended, if local susceptibility levels
are lower, than 90%; therefore, the use of several tested
drugs (ceftriaxone, sulphamethoxazole/trimethoprim,
ciprofloxacin and cefepime) empirically is not wise. Our
results are especially daunting in regards to b-lactam
antibiotics (coupled with the instrinsic resistance already
present in these bacteria), as in several vulnerable
patient groups (e.g. children and pregnant women)
there are the first-choice therapeutic alternatives [2,4].
Due to the emergence of antimicrobial resistance, the
submission of samples suspected of infection and the
adjusting of therapy based on the final antibiogram is of
utmost importance.
In conclusion, a total of 193 individual isolates were
identified (A. hydrophila, A. caviae and A. veronii in high-
est numbers). Wounds samples (lacerations, punctures
and avulsions) were the most common sample type, fol-
lowed by abscesses and surgical samples. The median
age of the affected patients was 61 years overall. The
highest resistance levels overall were observed for cef-
triaxone, sulphamethoxazole/trimethoprim, ciprofloxacin
and cefepime, while 70.9% of cases, the reported
empiric therapy was inappropriate (ampicillin). Although
these bacteria thought to be infrequent pathogens, their
clinical relevance and prevalence is increasing in the era
of complex surgeries, severely immunosuppressed
patients (mainly due to malignant diseases and organ
transplantation) and current diagnostic technologies.
Due to the emergence of antimicrobial resistance, the
submission of samples suspected of infection and the
adjusting of therapy based on the final antibiogram is of
utmost importance.
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